The Experts below are selected from a list of 11460 Experts worldwide ranked by ideXlab platform

Julio Nunez - One of the best experts on this subject based on the ideXlab platform.

  • differential prognostic value of galectin 3 according to Carbohydrate Antigen 125 levels in transcatheter aortic valve implantation
    Revista Espanola De Cardiologia, 2019
    Co-Authors: Tobias Rheude, Julio Nunez, Vicent Bodi, Costanza Pellegrini, Michael Joner, Teresa Trenkwalder, Patrick N Mayr, Stefan Holdenrieder, Wolfgang Koenig, Albert M Kasel
    Abstract:

    Abstract Introduction and objectives Galectin-3 (Gal-3) and Carbohydrate Antigen 125 (CA125) have been associated with adverse outcomes after transcatheter aortic valve implantation (TAVI). Experimental data have suggested a potential molecular interaction. Therefore, we assessed the association of Gal-3 and CA125 with prognosis after TAVI. Methods A total of 439 patients were enrolled. The primary endpoint was a composite of all-cause mortality or readmission for worsening heart failure after TAVI. Results The primary endpoint occurred in 16.4%. Gal-3 was dichotomized at ≥ 8.71 ng/mL into elevated and not elevated. Gal-3 was elevated in 31.9% and was associated with a higher risk of the primary endpoint (25% vs 12.4%, HR, 2.26; P  Conclusions In patients undergoing TAVI, Gal-3 predicted adverse clinical outcomes only when CA125 was elevated.

  • long term serial kinetics of n terminal pro b type natriuretic peptide and Carbohydrate Antigen 125 for mortality risk prediction following acute heart failure
    European heart journal. Acute cardiovascular care, 2017
    Co-Authors: Julio Nunez, Eduardo Nunez, Gregg C Fonarow, Vicent Bodi, Gema Minana, Sergio Garciablas, Antoni Bayesgenis, Domingo A Pascualfigal, Enrique Santas, Francisco J Chorro
    Abstract:

    Aim:Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and Carbohydrate Antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit of using longitudinal values, and how this predictive ability is modified when modelling together. The aim of this study was to determine the mutually-adjusted association between the longitudinal trajectories of NT-proBNP and CA125 with all-cause mortality after an episode of AHF.Methods and results:We included 946 consecutive patients discharged for AHF. NT-proBNP and CA125 were measured at each physician-patient encounter (median (interquartile range (IQR)):3 (2–4)). The effect on mortality (time-dependent modelling) was assessed using joint modelling (JM) and multi-state Markov. The mean age was 71±11 years and 51% exhibited left ventricular systolic dysfunction. At a median follow-up of 2.64 years (IQR=1.20–5.36), 498 patients died (52.6%). The observed trajec...

  • comparison of Carbohydrate Antigen 125 and n terminal pro brain natriuretic peptide for risk prediction after transcatheter aortic valve implantation
    American Journal of Cardiology, 2017
    Co-Authors: Tobias Rheude, Julio Nunez, Costanza Pellegrini, Michael Joner, Teresa Trenkwalder, Patrick N Mayr, Stefan Holdenrieder, Albert M Kasel, Hans Schmid, Juan Sanchis
    Abstract:

    Elevated Carbohydrate Antigen 125 (CA125) and N-terminal pro-brain natriuretic peptide (NTproBNP) have been associated with adverse outcome after transcatheter aortic valve implantation (TAVI). This study performs a comparison of both biomarkers for prognosis after TAVI. The study includes 363 patients. The primary end point was all-cause death or readmission for worsening congestive heart failure within 1 year after TAVI, and this end point occurred in 16% of the population. The optimal cutoff to predict the primary end point was 18.4 U/ml for CA125 and 2,570 ng/L for NTproBNP. Elevated CA125 levels were present in 52% and were associated with a higher rate of the primary end point (27% vs 3%; p

  • Carbohydrate Antigen 125 guided therapy in acute heart failure chance hf a randomized study
    Jacc-Heart Failure, 2016
    Co-Authors: Julio Nunez, Vicent Bodi, Vicente Bertomeugonzalez, Pau Llacer, Maria J Bosch, Pilar Merlos, Sergio Garciablas, Vicente Montagud, Vicente Bertomeumartinez, Valle Pedrosa
    Abstract:

    Abstract Objectives This study sought to evaluate the prognostic effect of Carbohydrate Antigen-125 (CA125)–guided therapy (CA125 strategy) versus standard of care (SOC) after a hospitalization for acute heart failure (AHF). Background CA125 has emerged as a surrogate of fluid overload and inflammatory status in AHF. After an episode of AHF admission, elevated values of this marker at baseline as well as its longitudinal profile relate to adverse outcomes, making it a potential tool for treatment guiding. Methods In a prospective multicenter randomized trial, 380 patients discharged for AHF and high CA125 were randomly assigned to the CA125 strategy (n = 187) or SOC (n = 193). The aim in the CA125 strategy was to reduce CA125 to ≤35 U/ml by up or down diuretic dose, enforcing the use of statins, and tightening patient monitoring. The primary endpoint was 1-year composite of death or AHF readmission. Treatment strategies were compared as a time to first event and longitudinally. Results Patients allocated to the CA125 strategy were more frequently visited, and treated with ambulatory intravenous loop diuretics and statins. Likewise, doses of oral loop diuretics and aldosterone receptor blockers were more frequently modified. The CA125 strategy resulted in a significant reduction of the primary endpoint, whether evaluated as time to first event (66 events vs. 84 events; p = 0.017) or as recurrent events (85 events vs. 165 events; incidence rate ratio: 0.49; 95% confidence interval: 0.28 to 0.82; p = 0.008). The effect was driven by significantly reducing rehospitalizations but not mortality. Conclusions The CA125 strategy was superior to the SOC in terms of reducing the risk of the composite of 1-year death or AHF readmission. This effect was mainly driven by significantly reducing the rate of rehospitalizations. (Carbohydrate Antigen-125-guided Therapy in Heart Failure [CHANCE-HF]; NCT02008110)

  • tumor marker Carbohydrate Antigen 125 predicts adverse outcome after transcatheter aortic valve implantation
    Jacc-cardiovascular Interventions, 2013
    Co-Authors: Oliver Husser, Julio Nunez, Juan Sanchis, Eduardo Nunez, Andreas Holzamer, Daniele Camboni, Andreas Luchner, Vicente Bodi, Gunter A J Riegger, Christof Schmid
    Abstract:

    Objectives This study sought to predict the value of tumor marker Carbohydrate Antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]). Background Risk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need. Methods CA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transformation and dichotomized by its median value (M1 ≤15.7 U/ml vs. M2 >15.7 U/ml). Results At a median follow-up of 183 days (interquartile range: 63 to 365) and 144 days (interquartile range: 56 to 365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A 3-fold increase in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both Conclusions Serum levels of CA125 before and after TAVI independently predict death and MACE.

Timothy A Woodward - One of the best experts on this subject based on the ideXlab platform.

  • neutrophil gelatinase associated lipocalin macrophage inhibitory cytokine 1 and Carbohydrate Antigen 19 9 in pancreatic juice pathobiologic implications in diagnosing benign and malignant disease of the pancreas
    Pancreas, 2013
    Co-Authors: Sukwinder Kaur, Michael J Baine, Sushovan Guha, Nobuo Ochi, Subhankar Chakraborty, Kavita Mallya, Colleen S Thomas, Julia E Crook, Michael B Wallace, Timothy A Woodward
    Abstract:

    OBJECTIVE Pancreatic diseases pose significant diagnostic challenge as signs and symptoms often overlap. We investigated the potential of pancreatic juice neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1 (MIC-1), and Carbohydrate Antigen 19-9 (CA19-9) to aid in the diagnosis of patients with symptoms suggestive of pancreatic diseases. METHODS A total of 105 chronic pancreatitis (CP), pancreatic cancer (PC), and nonpancreatic nonhealthy (patients with symptoms mimicking pancreatic disease but found to be free of any pancreatic disease) patients underwent endoscopic pancreatic juice collection after secretin stimulation. Neutrophil gelatinase-associated lipocalin and MIC-1 levels were measured by enzyme-linked immunosorbent assay, whereas CA19-9 was measured by radioimmunoassay. RESULTS Neutrophil gelatinase-associated lipocalin, MIC-1, and CA19-9 were significantly elevated in the pancreatic juice of patients with CP and patients with PC as compared with nonpancreatic nonhealthy controls (P ≤ 0.034). Neutrophil gelatinase-associated lipocalin seemed most promising in differentiating diseased versus nondiseased pancreata (areas under the curve, 0.88-0.91), whereas MIC-1 was found to be higher in patients with PC than in patients with CP (P = 0.043). Interestingly, MIC-1 levels in diabetic patients with PC were higher than in nondiabetic patients with PC (P = 0.030) and diabetic patients with CP (P = 0.087). Carbohydrate Antigen 19-9 showed the least ability to distinguish patient groups (areas under the curve, 0.61-0.76). CONCLUSIONS Pancreatic juice neutrophil gelatinase-associated lipocalin shows potential utility in establishing pancreatic etiology in the context of nonspecific symptoms, whereas MIC-1 may aid in differentiating PC from CP.

  • neutrophil gelatinase associated lipocalin macrophage inhibitory cytokine 1 and Carbohydrate Antigen 19 9 in pancreatic juice pathobiologic implications in diagnosing benign and malignant disease of the pancreas
    Pancreas, 2013
    Co-Authors: Sukhwinder Kaur, Michael J Baine, Sushovan Guha, Nobuo Ochi, Subhankar Chakraborty, Kavita Mallya, Colleen S Thomas, Julia E Crook, Michael B Wallace, Timothy A Woodward
    Abstract:

    ObjectivePancreatic diseases pose significant diagnostic challenge as signs and symptoms often overlap. We investigated the potential of pancreatic juice neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1 (MIC-1), and Carbohydrate Antigen 19-9 (CA19-9) to aid in the diagnos

Juan Sanchis - One of the best experts on this subject based on the ideXlab platform.

  • comparison of Carbohydrate Antigen 125 and n terminal pro brain natriuretic peptide for risk prediction after transcatheter aortic valve implantation
    American Journal of Cardiology, 2017
    Co-Authors: Tobias Rheude, Julio Nunez, Costanza Pellegrini, Michael Joner, Teresa Trenkwalder, Patrick N Mayr, Stefan Holdenrieder, Albert M Kasel, Hans Schmid, Juan Sanchis
    Abstract:

    Elevated Carbohydrate Antigen 125 (CA125) and N-terminal pro-brain natriuretic peptide (NTproBNP) have been associated with adverse outcome after transcatheter aortic valve implantation (TAVI). This study performs a comparison of both biomarkers for prognosis after TAVI. The study includes 363 patients. The primary end point was all-cause death or readmission for worsening congestive heart failure within 1 year after TAVI, and this end point occurred in 16% of the population. The optimal cutoff to predict the primary end point was 18.4 U/ml for CA125 and 2,570 ng/L for NTproBNP. Elevated CA125 levels were present in 52% and were associated with a higher rate of the primary end point (27% vs 3%; p

  • tumor marker Carbohydrate Antigen 125 predicts adverse outcome after transcatheter aortic valve implantation
    Jacc-cardiovascular Interventions, 2013
    Co-Authors: Oliver Husser, Julio Nunez, Juan Sanchis, Eduardo Nunez, Andreas Holzamer, Daniele Camboni, Andreas Luchner, Vicente Bodi, Gunter A J Riegger, Christof Schmid
    Abstract:

    Objectives This study sought to predict the value of tumor marker Carbohydrate Antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]). Background Risk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need. Methods CA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transformation and dichotomized by its median value (M1 ≤15.7 U/ml vs. M2 >15.7 U/ml). Results At a median follow-up of 183 days (interquartile range: 63 to 365) and 144 days (interquartile range: 56 to 365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A 3-fold increase in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both Conclusions Serum levels of CA125 before and after TAVI independently predict death and MACE.

  • benefits of statin therapy based on plasma Carbohydrate Antigen 125 values following an admission for acute heart failure
    Revista Espanola De Cardiologia, 2011
    Co-Authors: Julio Nunez, Juan Sanchis, Eduardo Nunez, Gregg C Fonarow, Vicent Bodi, Vicente Bertomeugonzalez, Gema Minana, Patricia Palau, Lorenzo Facila, Francisco J Chorro
    Abstract:

    A B S T R A C T Introduction and objectives: The prognostic benefit of statins in patients with heart failure is a topic of controversy. Under the hypothesis that statins may provide greater benefit in a subgroup of patients with heightened inflammatory activity, we sought to explore whether statins are associated with a decreased risk of long-term mortality in patients with acute heart failure based on elevated levels of Carbohydrate Antigen 125, a biomarker related to systemic congestion and proinflammatory status. Methods: We analysed 1222 consecutive patients admitted with acute heart failure in a single teaching center during a median follow-up of 20 months. Carbohydrate Antigen 125 was measured during index hospitalization and dichotomized according to the established reference cut-off (>35 U/mL). Results: Increased levels of Carbohydrate Antigen 125 (>35 U/mL) were observed in 793 (64.9%) and prescription of statins registered in 455 (37.2%) patients. In patients with Carbohydrate Antigen 125 >35 U/mL, mortality was lower in statin-treated patients (1.89 vs 2.80 per 10 patient-years of follow-up, P 35 U/mL) identified a subset of patients with acute heart failure who could benefit from statin treatment in regard to total mortality.

  • Carbohydrate Antigen 125 an emerging prognostic risk factor in acute heart failure
    Heart, 2007
    Co-Authors: Julio Nunez, Juan Sanchis, Eduardo Nunez, Vicent Bodi, Vicente Bertomeugonzalez, Maria J Bosch, Luciano Consuegra, Angel Martinezbrotons, Rocio Robles, Lorenzo Facila
    Abstract:

    Objective: To assess whether circulating levels of Carbohydrate Antigen 125 (CA125) predict subsequent 6-month all-cause mortality in patients after the index hospitalisation for acute heart failure (HF). Design and setting: Prospective cohort study at a single teaching centre in Spain. Methods: 529 consecutive patients with acute HF admitted in a single university centre were analysed. In addition to the traditional clinical information, CA125 (U/ml) was measured during the early course of hospitalisation. The independent association between baseline CA125 and mortality was assessed with Cox regression analysis. The follow-up was limited to 6 months. Results: 349 (66%) patients showed serum levels of CA125 >35 U/ml (established cut-off point value). At a 6-month follow-up, 89 (16.8%) deaths were identified. A positive trend between mortality and CA125 quartiles was observed; 3.8%, 15.2%, 22% and 26.5% of deaths occurred from quartile 1 to 4 of CA125 (p Conclusions: Serum levels of CA125 obtained in patients admitted with a diagnosis of acute HF was shown to be an independent predictor of mortality up to the 6-month follow-up.

Vicent Bodi - One of the best experts on this subject based on the ideXlab platform.

  • differential prognostic value of galectin 3 according to Carbohydrate Antigen 125 levels in transcatheter aortic valve implantation
    Revista Espanola De Cardiologia, 2019
    Co-Authors: Tobias Rheude, Julio Nunez, Vicent Bodi, Costanza Pellegrini, Michael Joner, Teresa Trenkwalder, Patrick N Mayr, Stefan Holdenrieder, Wolfgang Koenig, Albert M Kasel
    Abstract:

    Abstract Introduction and objectives Galectin-3 (Gal-3) and Carbohydrate Antigen 125 (CA125) have been associated with adverse outcomes after transcatheter aortic valve implantation (TAVI). Experimental data have suggested a potential molecular interaction. Therefore, we assessed the association of Gal-3 and CA125 with prognosis after TAVI. Methods A total of 439 patients were enrolled. The primary endpoint was a composite of all-cause mortality or readmission for worsening heart failure after TAVI. Results The primary endpoint occurred in 16.4%. Gal-3 was dichotomized at ≥ 8.71 ng/mL into elevated and not elevated. Gal-3 was elevated in 31.9% and was associated with a higher risk of the primary endpoint (25% vs 12.4%, HR, 2.26; P  Conclusions In patients undergoing TAVI, Gal-3 predicted adverse clinical outcomes only when CA125 was elevated.

  • long term serial kinetics of n terminal pro b type natriuretic peptide and Carbohydrate Antigen 125 for mortality risk prediction following acute heart failure
    European heart journal. Acute cardiovascular care, 2017
    Co-Authors: Julio Nunez, Eduardo Nunez, Gregg C Fonarow, Vicent Bodi, Gema Minana, Sergio Garciablas, Antoni Bayesgenis, Domingo A Pascualfigal, Enrique Santas, Francisco J Chorro
    Abstract:

    Aim:Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and Carbohydrate Antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit of using longitudinal values, and how this predictive ability is modified when modelling together. The aim of this study was to determine the mutually-adjusted association between the longitudinal trajectories of NT-proBNP and CA125 with all-cause mortality after an episode of AHF.Methods and results:We included 946 consecutive patients discharged for AHF. NT-proBNP and CA125 were measured at each physician-patient encounter (median (interquartile range (IQR)):3 (2–4)). The effect on mortality (time-dependent modelling) was assessed using joint modelling (JM) and multi-state Markov. The mean age was 71±11 years and 51% exhibited left ventricular systolic dysfunction. At a median follow-up of 2.64 years (IQR=1.20–5.36), 498 patients died (52.6%). The observed trajec...

  • Carbohydrate Antigen 125 guided therapy in acute heart failure chance hf a randomized study
    Jacc-Heart Failure, 2016
    Co-Authors: Julio Nunez, Vicent Bodi, Vicente Bertomeugonzalez, Pau Llacer, Maria J Bosch, Pilar Merlos, Sergio Garciablas, Vicente Montagud, Vicente Bertomeumartinez, Valle Pedrosa
    Abstract:

    Abstract Objectives This study sought to evaluate the prognostic effect of Carbohydrate Antigen-125 (CA125)–guided therapy (CA125 strategy) versus standard of care (SOC) after a hospitalization for acute heart failure (AHF). Background CA125 has emerged as a surrogate of fluid overload and inflammatory status in AHF. After an episode of AHF admission, elevated values of this marker at baseline as well as its longitudinal profile relate to adverse outcomes, making it a potential tool for treatment guiding. Methods In a prospective multicenter randomized trial, 380 patients discharged for AHF and high CA125 were randomly assigned to the CA125 strategy (n = 187) or SOC (n = 193). The aim in the CA125 strategy was to reduce CA125 to ≤35 U/ml by up or down diuretic dose, enforcing the use of statins, and tightening patient monitoring. The primary endpoint was 1-year composite of death or AHF readmission. Treatment strategies were compared as a time to first event and longitudinally. Results Patients allocated to the CA125 strategy were more frequently visited, and treated with ambulatory intravenous loop diuretics and statins. Likewise, doses of oral loop diuretics and aldosterone receptor blockers were more frequently modified. The CA125 strategy resulted in a significant reduction of the primary endpoint, whether evaluated as time to first event (66 events vs. 84 events; p = 0.017) or as recurrent events (85 events vs. 165 events; incidence rate ratio: 0.49; 95% confidence interval: 0.28 to 0.82; p = 0.008). The effect was driven by significantly reducing rehospitalizations but not mortality. Conclusions The CA125 strategy was superior to the SOC in terms of reducing the risk of the composite of 1-year death or AHF readmission. This effect was mainly driven by significantly reducing the rate of rehospitalizations. (Carbohydrate Antigen-125-guided Therapy in Heart Failure [CHANCE-HF]; NCT02008110)

  • benefits of statin therapy based on plasma Carbohydrate Antigen 125 values following an admission for acute heart failure
    Revista Espanola De Cardiologia, 2011
    Co-Authors: Julio Nunez, Juan Sanchis, Eduardo Nunez, Gregg C Fonarow, Vicent Bodi, Vicente Bertomeugonzalez, Gema Minana, Patricia Palau, Lorenzo Facila, Francisco J Chorro
    Abstract:

    A B S T R A C T Introduction and objectives: The prognostic benefit of statins in patients with heart failure is a topic of controversy. Under the hypothesis that statins may provide greater benefit in a subgroup of patients with heightened inflammatory activity, we sought to explore whether statins are associated with a decreased risk of long-term mortality in patients with acute heart failure based on elevated levels of Carbohydrate Antigen 125, a biomarker related to systemic congestion and proinflammatory status. Methods: We analysed 1222 consecutive patients admitted with acute heart failure in a single teaching center during a median follow-up of 20 months. Carbohydrate Antigen 125 was measured during index hospitalization and dichotomized according to the established reference cut-off (>35 U/mL). Results: Increased levels of Carbohydrate Antigen 125 (>35 U/mL) were observed in 793 (64.9%) and prescription of statins registered in 455 (37.2%) patients. In patients with Carbohydrate Antigen 125 >35 U/mL, mortality was lower in statin-treated patients (1.89 vs 2.80 per 10 patient-years of follow-up, P 35 U/mL) identified a subset of patients with acute heart failure who could benefit from statin treatment in regard to total mortality.

  • Carbohydrate Antigen 125 an emerging prognostic risk factor in acute heart failure
    Heart, 2007
    Co-Authors: Julio Nunez, Juan Sanchis, Eduardo Nunez, Vicent Bodi, Vicente Bertomeugonzalez, Maria J Bosch, Luciano Consuegra, Angel Martinezbrotons, Rocio Robles, Lorenzo Facila
    Abstract:

    Objective: To assess whether circulating levels of Carbohydrate Antigen 125 (CA125) predict subsequent 6-month all-cause mortality in patients after the index hospitalisation for acute heart failure (HF). Design and setting: Prospective cohort study at a single teaching centre in Spain. Methods: 529 consecutive patients with acute HF admitted in a single university centre were analysed. In addition to the traditional clinical information, CA125 (U/ml) was measured during the early course of hospitalisation. The independent association between baseline CA125 and mortality was assessed with Cox regression analysis. The follow-up was limited to 6 months. Results: 349 (66%) patients showed serum levels of CA125 >35 U/ml (established cut-off point value). At a 6-month follow-up, 89 (16.8%) deaths were identified. A positive trend between mortality and CA125 quartiles was observed; 3.8%, 15.2%, 22% and 26.5% of deaths occurred from quartile 1 to 4 of CA125 (p Conclusions: Serum levels of CA125 obtained in patients admitted with a diagnosis of acute HF was shown to be an independent predictor of mortality up to the 6-month follow-up.

Qin Wei - One of the best experts on this subject based on the ideXlab platform.

  • ultrasensitive electrochemical immunosensor for Carbohydrate Antigen 72 4 based on dual signal amplification strategy of nanoporous gold and polyaniline au asymmetric multicomponent nanoparticles
    Biosensors and Bioelectronics, 2015
    Co-Authors: Haixia Fan, Zhankui Guo, Liang Gao, Yong Zhang, Dawei Fan, Qin Wei
    Abstract:

    A sandwich electrochemical immunosensor is described for Carbohydrate Antigen 72-4 (CA72-4) based on a dual amplification strategy with nanoporous gold (NPG) film as the sensor platform and polyaniline-Au asymmetric multicomponent nanoparticles (PANi-Au AMNPs) as labels. In this study, the second anti-CA72-4 antibody (Ab2) adsorbed onto the Au of the PANi-Au AMNPs, which could be simply synthesized by interfacial reaction and have many characteristics of polyaniline and Au nanoparticle, such as well-controlled size, high conductivity, biocompatibility and catalysis. NPG film was used as electrode substrate material to fix a large number of antibodies, due to its unique properties: good biocompatibility, high conductivity, large surface area, and stability. The synergetic of NPG film and PANi-Au AMNPs could increase signal response, and significantly improve sensitivity of the immunosensor. The proposed immunosensor exhibited a wide linear range from 2 to 200 U/mL, with a detection limit of 0.10 U/mL CA72-4, good reproducibility, selectivity and stability. This new type of labels for immunosensors may provide many potential applications in the detection of Carbohydrate Antigen in immunoassays.

  • an electrochemical immunosensor for ultrasensitive detection of Carbohydrate Antigen 199 based on au cuxos yolk shell nanostructures with porous shells as labels
    Biosensors and Bioelectronics, 2015
    Co-Authors: Aiping Guo, Wei Cao, Xianchao Meng, Qin Wei
    Abstract:

    Abstract A novel and sensitive electrochemical immunosensor for ultrasensitive detection of pancreatic cancer biomarker Carbohydrate Antigen 199 (CA199) was proposed by using Au@Cu x OS yolk–shell nanostructures with porous shells as labels for signal amplification. Au@Cu x OS yolk–shell nanostructures exhibit high electrocatalytic activity toward the reduction of hydrogen peroxide (H 2 O 2 ) as analytical signal. Moreover, secondary antibody (Ab 2 ) can adsorb on the surface of Au@Cu x OS with porous shells which has large surface area and could greatly increase the probability of Ab 2 –Antigen interactions thereby leading to higher sensitivity. Reduced graphene oxide–tetraethylene pentamine (rGO–TEPA), containing abundant amine groups, was supported Au nanoparticles as a support platform to immobilize the primary antibody (Ab 1 ). The resulting sensing interface of rGO–TEPA/AuNPs could provide a large electroconductive surface area, allowing high loadings of the biological recognition elements as well as the occurrence of electrocatalytic and electron-transfer processes. Under optimal conditions, the immunosensor exhibited a wide linear response to CA199 ranging from 0.001 to 12 U/mL with a low detection limit of 0.0005 U/mL. The designed immunosensor displayed good precision, high sensitivity, acceptable stability and reproducibility, and has been applied to the analysis of serum with satisfactory results. The proposed method provides a new promising platform of clinical immunoassay for other biomolecules.

  • ionic liquid functionalized graphene based immunosensor for sensitive detection of Carbohydrate Antigen 15 3 integrated with cd2 functionalized nanoporous tio2 as labels
    Biosensors and Bioelectronics, 2014
    Co-Authors: Lifang Zhao, Qin Wei, Jinke Dou
    Abstract:

    Abstract A novel electrochemical immunosensor for sensitive detection of Carbohydrate Antigen 15-3 (CA15-3) based on dual signal amplification strategy of ionic liquid functionalized graphene and Cd 2+ -functionalized nanoporous TiO 2 (f-TiO 2 –Cd 2+ ) has been developed. Ionic liquid functionalized graphene was used to anchor primary CA15-3 antibody (Ab 1 ). f-TiO 2 –Cd 2+ was employed to immobilize secondary cancer Antigen 15-3 (CA15-3) antibody (Ab 2 ) and the resulting nanocomposite (Ab 2 –f-TiO 2 –Cd 2+ ) was used as trace tag for signal amplification. The fabricated immumosensor displayed a wide range of linear response (0.02–60 U/mL), ultra-low detection limit (0.008 U/mL), good reproducibility, selectivity and stability towards CA15-3. The good performance of the immunosensor can be attributed to (1) high surface-to-volume ratio of graphene which allows high-level immobilization of Ab 1 , (2) excellent biocompatibility and electron transfer rate originating from ionic liquid functionalized graphene, (3) a highly specific surface area of nanoporous TiO 2 that facilitates the adsorption of high amount of Cd 2+ for signal amplification.